StockMacro
Menu

BlossomHill Therapeutics

$14.51 -9.3% in 6 monthsMarket cap $461.2M

BLSM on XNAS, Health Care, BlossomHill Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Cash of $224.9M against a $458M market value, with shares down 7% in a month.

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.

Industry
Pharmaceutical preparations (Health Care)
Employees
71
Website
bhtherapeutics.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $24.0M.
Quarter to 30 Jun 2025: revenue –, net income -$13.2MQuarter to 30 Sep 2025: revenue –, net income -$16.0MQuarter to 30 Jun 2026: revenue –, net income -$23.8MQuarter to 30 Sep 2026: revenue –, net income -$24.0M
30 Jun 2025RevenueNet incomeNet losstallest bar $24.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$24.0M
30 Jun 2026–-$23.8M
30 Sep 2025–-$16.0M
30 Jun 2025–-$13.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. – –
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $224.9M $67.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $6.64
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. – 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.2 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
BlossomHill TherapeuticsBLSM (this company) $461.2M––––
Gyre TherapeuticsGYRE $460.8Mloss4.0+8.4%-30.1%
NeurogeneNGNE $458.5Mloss–––
Monopar TherapeuticsMNPR $467.6Mloss–––
Assembly BiosciencesASMB $454.4Mloss6.8+80%-16.6%
Shattuck LabsSTTK $454.2Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

53%

16.9M shares held by 13F filers (30 Sep 2026) of 31.8M outstanding (10 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.9%

590K shares sold short (30 Oct 2026) of 31.8M outstanding (10 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.7

590K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+22%

485K shares sold short in the report before, 590K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

66%

66% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

6

6 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

6 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $14.51 on 20 Nov 2026, -9.3% over 12 months (12-month range $12.35 to $26.82)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $15.2M in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months, 0% on the 12 months before.
Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.
Institutional holders (13F filers). 39 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
11 Aug 2026Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 5.2M)
3 Aug 20268-K and other filingsRegistered new securities for sale (S-1)
17 Jul 20268-K and other filingsRegistered new securities for sale (S-1)
10 Dec 20258-K and other filingsPrivate placement of securities (Form D)
2 Jan 20248-K and other filingsPrivate placement of securities (Form D)
Insider net buying (open market)
Month from 1 Aug 2026: $15.2M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Jul 2026: 1 published
Capital spending per quarter
Quarter ended 30 Sep 2025: $22K; public on 13 Nov 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
30 Sep 2026 report: 39; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $10.0M (12 Aug 2026), 1.9× its normal reading.
  • Clustered insider buying: had 4 insiders buy $5.2M of its shares on the open market within 30 days (4 filings) Public on 11 Aug 2026.
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months, 0% on the 12 months before.
  • Capital spending per quarter: Capital spending $0 in the latest quarter, -100% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 6 insider trades

No trades in the last 90 days; the latest was filed 12 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Aug 2026OrbiMed Capital GP VIII LLC and 1 otherDirectorBuy625,000$16.00$10.0MForm 4
10 Aug 2026Vincent Paul LiptakGeneral CounselBuy4,700$15.89$75KForm 4
10 Aug 2026Cormorant Private Healthcare Fund VI, LP and 5 others10% ownerBuy312,500$16.00$5.0MForm 4
10 Aug 2026Jason A KeyesChief Financial OfficerBuy700$16.00$11KForm 4
10 Aug 2026John P. SchmidDirectorBuy6,000$16.00$96KForm 4

39 institutions reported shares at the end of Q3 2026, 53% of the shares outstanding; 38 opened a position, 0 sold out. From 13F reports.

InstitutionShares% of companyValueChange
Cormorant Asset Management, LP3.6M11.4%$67.4M
Orbimed Advisors LLC2.7M8.54%$50.6M
Perceptive Advisors LLC1.8M5.70%$33.8M
Vivo Capital, LLC1.5M4.70%$27.8M
Deerfield Management Company, L.P.1.4M4.55%$27.0M
JPMorgan Chase & Co1.4M4.45%$30.2M
Janus Henderson Group Ltd.1.3M4.21%$24.9M
FMR LLC (Fidelity)1.0M3.23%$19.1M
Vanguard Capital Management LLC433K1.36%$8.1M
NEXTBio Capital Management LP250K0.79%$4.7M

Company events

All 6 company events

In 12 months: 2 share registrations, 1 private placement. Results releases and routine reports are left out.

FiledWhat happenedSource
3 Aug 2026Registered new securities for sale (S-1)S-1/A
16 Jul 2026Registered new securities for sale (S-1)S-1
10 Dec 2025Private placement of securities (Form D)$84.2M sold of $84.2M offeredD
2 Jan 2024Private placement of securities (Form D)$88.6M sold of $100.0M offeredD
1 Mar 2021Private placement of securities (Form D)$71.0M sold of $71.0M offeredD
11 Jan 2021Private placement of securities (Form D)$2.0M sold of $2.0M offeredD

The 5 newest of 82 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 13 Aug 2026Insiders record

    OrbiMed Capital GP VIII LLC (director) and 1 other(s) bought 625,000 shares of BLSM ($10.0M) (dated 12 Aug 2026)

  2. 13 Aug 2026Insiders record

    GORDON CARL L (director) bought 625,000 shares of BLSM [same transaction as an earlier filing] (dated 12 Aug 2026)

  3. 11 Aug 2026Insiders change

    had 4 insiders buy $5.2M of its shares on the open market within 30 days (4 filings).

    Who bought: Schmid John P., Keyes Jason A, Liptak Vincent Paul.

    See the evidence (4 source records)
    Independent buyers
    4
    Purchase filings (Form 4, code P)
    4
    Total bought
    $5.2M
    Window
    12 Jul 2026 to 11 Aug 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  4. 11 Aug 2026Insiders record

    Liptak Vincent Paul (General Counsel) bought 4,700 shares of BLSM ($74,700) (dated 10 Aug 2026)

  5. 11 Aug 2026Insiders record

    Cormorant Private Healthcare Fund VI, LP (ten percent owner) and 5 other(s) bought 312,500 shares of BLSM ($5.0M) (dated 10 Aug 2026)

  6. 11 Aug 2026Insiders record

    Keyes Jason A (Chief Financial Officer) bought 700 shares of BLSM ($11,200) (dated 10 Aug 2026)

  7. 11 Aug 2026Insiders record

    Schmid John P. (director) bought 6,000 shares of BLSM ($96,000) (dated 10 Aug 2026)

  8. 3 Aug 2026Filings record

    Registered new securities for sale (S-1)

  9. 17 Jul 2026Filings record

    Registered new securities for sale (S-1) (dated 16 Jul 2026)

  10. 10 Dec 2025Filings record

    Private placement of securities (Form D)

  11. 2 Jan 2024Filings record

    Private placement of securities (Form D)

  12. 1 Mar 2021Filings record

    Private placement of securities (Form D)

  13. 11 Jan 2021Filings record

    Private placement of securities (Form D)

Not listed: 5 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001839970
Ticker
BLSM
Domain
bhtherapeutics.com
Employer name
BlossomHill Therapeutics, Inc. (1 unverified)
Fein
85-1578711 (1 unverified)
Hq location
CA|SAN DIEGO| (1 unverified)
Name
BlossomHill Therapeutics, Inc.
  • DOL H-1B labor condition applications and PERM certifications10 data points9 Dec 2024 to 13 Apr 2026
  • SEC Form 13F institutional holdings9 data points30 Sep 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)11 records11 Jan 2021 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)42 data points31 Dec 2024 to 10 Nov 2026
  • SEC Form 4 insider transactions6 records, 8 data points10 Aug 2026 to 12 Aug 2026
  • FINRA short interest (twice monthly)17 data points14 Aug 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)150 data points7 Aug 2026 to 20 Nov 2026